Trending News Today: Study Shows Taltz Superior to Humira in Active Psoriatic Arthritis

Eli Lilly’s psoriatic arthritis drug Taltz proved to be more effective than AbbVie’s Humira in a late-stage clinical trial, Reuters reported. According to the article, the trial tested Taltz and the standard-of-care Humira in patients with active psoriatic arthritis. The study showed that Taltz was as effective as Humira in improving symptoms of psoriatic arthritis but was superior to Humira in clearing skin completely in a greater number of patients and achieving both results simultaneously, Reuters reported.
A recent poll found approximately 3 in 10 Americans delayed seeking medical treatment within the past year due to medical costs, according to The Hill. The Gallup poll showed that 29% of respondents put off treatment because of cost and approximately 19% said they delayed treatment for serious or somewhat serious conditions, the article noted. An average of 30% of respondents said they had put off treatment each year because of costs since 2005, up from 24% in the 4 years before that, according to the poll.  
US Surgeon General Jerome Adams warned about the risks of e-cigarette use in children and teens in an advisory on Tuesday, the Associated Press reported. The surgeon general’s advisory said parents, health professionals, and government officials must take “aggressive steps” to keep minors from using e-cigarettes. Separate survey results released Monday showed twice as many high school students used e-cigarettes this year compared with last year, the article noted.

Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 

Related Articles

Upadacitinib (Rinvoq, AbbVie) is indicated for adults with moderate-to-severe rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.
Top news of the day from across the health care landscape.
Top news of the day from across the health care landscape.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2019
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.